BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 4
• 5
• 6
• 7
• 8
• 11
• 12
• 13
• 14
• 15
• 18
• 19
• 20
• 21
• 22
• 25
• 26
• 27
• 28
• 29
• 30

• Drug Development

  Introgen Therapeutics, Inc. Announces Positive Phase 2 Clinical Trial Results with INGN 225 Immunotherapy in Patients with Small Cell Lung Cancer

  June 4, 2007

   · 

  1 min read
• Drug Development

  KOSAN Biosciences, Inc. Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at American Society of Clinical Oncology

  June 4, 2007

   · 

  6 min read
• Biotech Bay

  Applied Biosystems Announces Early-Access Program For Its Next-Generation Sequencing Platform

  June 4, 2007

   · 

  1 min read
• BioForest

  Verathon Inc. Introduces GlideScope(R) Cobalt Single-Use Video Laryngoscope; Enables Fast Intubations; Eliminates Time-Consuming Disinfection

  June 4, 2007

   · 

  4 min read
• Drug Development

  Millennium Pharmaceuticals, Inc. (Cambridge, Massachusetts) VELCADE(R) (bortezomib) for Injection Based Therapies Produced High Complete Response Rates in Newly Diagnosed Non-Hodgkin’s Lymphoma Patients

  June 4, 2007

   · 

  9 min read
• BioForest

  Cell Therapeutics, Inc. Announces Filing of a Universal Shelf Registration

  June 4, 2007

   · 

  1 min read
• Drug Development

  ChemGenex Pharmaceuticals Limited Reports Successful Personalized Dosing of Quinamed at American Society of Clinical Oncology

  June 4, 2007

   · 

  1 min read
• Drug Development

  KOSAN Biosciences, Inc. Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at American Society of Clinical Oncology

  June 4, 2007

   · 

  5 min read
• Drug Development

  Genentech, Inc.: Updated Overall Survival Data From Pivotal Herceptin Adjuvant Studies in HER2-Positive Breast Cancer

  June 4, 2007

   · 

  1 min read
• Drug Development

  Micromet Final Data from a Phase 2 Trial Presented at American Society of Clinical Oncology Specifies Dose-dependent Activity of Adecatumumab (MT201)

  June 4, 2007

   · 

  7 min read